Valeo Financial Advisors LLC Invests $218,000 in IDEXX Laboratories, Inc. $IDXX

Valeo Financial Advisors LLC acquired a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 406 shares of the company’s stock, valued at approximately $218,000.

Several other hedge funds also recently bought and sold shares of the business. Vantage Investment Partners LLC grew its position in IDEXX Laboratories by 21.7% in the 2nd quarter. Vantage Investment Partners LLC now owns 64,765 shares of the company’s stock valued at $34,736,000 after acquiring an additional 11,548 shares during the last quarter. Marks Group Wealth Management Inc lifted its holdings in IDEXX Laboratories by 0.9% during the 2nd quarter. Marks Group Wealth Management Inc now owns 11,940 shares of the company’s stock valued at $6,404,000 after buying an additional 107 shares in the last quarter. Three Bridge Wealth Advisors LLC bought a new stake in IDEXX Laboratories during the 2nd quarter valued at about $243,000. Keudell Morrison Wealth Management purchased a new position in shares of IDEXX Laboratories during the second quarter worth approximately $208,000. Finally, Simplicity Wealth LLC purchased a new position in shares of IDEXX Laboratories during the second quarter worth approximately $201,000. Institutional investors own 87.84% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on IDXX. Stifel Nicolaus set a $640.00 price objective on IDEXX Laboratories in a research note on Monday, August 4th. Piper Sandler reiterated a “neutral” rating and issued a $700.00 target price (up from $510.00) on shares of IDEXX Laboratories in a report on Monday, August 11th. Leerink Partners lifted their price objective on IDEXX Laboratories from $580.00 to $600.00 and gave the company an “outperform” rating in a report on Thursday, July 17th. Weiss Ratings restated a “buy (b-)” rating on shares of IDEXX Laboratories in a report on Wednesday. Finally, BTIG Research raised their target price on shares of IDEXX Laboratories from $545.00 to $785.00 and gave the company a “buy” rating in a research report on Tuesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $656.50.

IDEXX Laboratories Trading Down 2.0%

NASDAQ:IDXX opened at $616.15 on Friday. The firm has a 50 day moving average of $641.49 and a 200 day moving average of $541.85. The stock has a market capitalization of $49.29 billion, a price-to-earnings ratio of 51.30, a PEG ratio of 4.07 and a beta of 1.58. The company has a quick ratio of 0.79, a current ratio of 1.11 and a debt-to-equity ratio of 0.31. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $688.12.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Monday, August 4th. The company reported $3.63 earnings per share for the quarter, topping the consensus estimate of $3.28 by $0.35. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The firm had revenue of $1.11 billion for the quarter, compared to the consensus estimate of $1.06 billion. During the same period in the previous year, the business earned $2.44 EPS. The firm’s revenue for the quarter was up 10.6% on a year-over-year basis. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. As a group, sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Insider Transactions at IDEXX Laboratories

In other IDEXX Laboratories news, EVP Sharon E. Underberg sold 5,450 shares of the company’s stock in a transaction that occurred on Friday, August 8th. The shares were sold at an average price of $651.60, for a total transaction of $3,551,220.00. Following the transaction, the executive vice president owned 6,156 shares in the company, valued at approximately $4,011,249.60. This represents a 46.96% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Michael Lane sold 8,411 shares of the company’s stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $627.74, for a total transaction of $5,279,921.14. Following the transaction, the executive vice president owned 7,132 shares in the company, valued at $4,477,041.68. The trade was a 54.11% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 54,057 shares of company stock worth $34,293,468 over the last ninety days. 0.98% of the stock is currently owned by insiders.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.